Cytokinetics, Incorporated

NASDAQ:CYTK

Biotechnology

Healthcare
$51.32 +3.86%

+$2.90 today

Market cap
$7.15B
Beta
0.43
P/E (TTM)
-11.6
EPS (TTM)
-$6.73
52W Low $31.99High $80.20

Volume 1.59M

Average 2.37M

CYTK Total Assets

Everything the company owns or controls; equal to total liabilities plus equity.

Cytokinetics, IncorporatedNASDAQ: CYTK

Total Assets · Q2 FY2026 · quarter ended Jun 2026

Total assets rises 57.0% from a year ago

Total assets stood at $1.92B at the end of Q2 FY2026, up 57.0% from a year earlier and up 51.1% from the prior quarter. Over 3 fiscal years it compounded at +12.0% a year.

Context

  • Total assets increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether total assets keeps rising in the next quarterly balance sheet after a +57.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$1.92B+51.1% QoQ
Last fiscal yearDec 2025
$1.42B+1.6% YoY
Year agoJun 2025
$1.23B+57.0% since
Total Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+57.0%——
1 year+1.6%——
3-year CAGR+12.0%——
5-year CAGR——
10-year CAGR——

Total Assets history

USD · from the balance sheet

Latest · FY2025
1.42B USD
Year-over-year change
+1.6%
4-year CAGR
+14.1%

Total Assets vs competitors

How CYTK compares with its peers on the latest reported figures

  • CYTK's Jun 2026 total assets of $1.92B is the highest of the 3 companies compared; the peer median is $213.72M.
  • Its year-over-year change of +57.0% is the highest of 2, against a peer median of -6.2%.
  • Over three fiscal years its annual growth of +12.0% compares with a peer median of -19.2%.
CYTK Competitors Peer median
Total Assets for CYTK and competitors
Company Period Latest balance YoY 3-year CAGR
CYTKCytokinetics, IncorporatedJun 2026$1.92B +57.0%+12.0%
RNAAtrium Therapeutics, Inc.Mar 2026$292.36M ——
TNYATenaya Therapeutics, Inc.Mar 2026$135.07M -6.2%-19.2%
KARDKardigan, Inc.—— ——
Peer median (excluding CYTK) $213.72M-6.2%-19.2%

Competitors are the stored peer set for CYTK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents112.67M65.58M113.02M94.86M122.52M
Short-term Investments358.97M717M501.8M981.16M759.7M
Net Receivables51.82M147K1.28M16.65M17.76M
Inventory00000
Other Current Assets012.46M015.28M16.99M
Total Current Assets535.67M795.19M628.05M1.11B916.98M
Property, Plant & Equipment (Net)146.41M163.19M147.74M140.97M155.17M
Goodwill00000
Intangible Assets00000
Long-term Investments152.05M46.71M40.53M145.06M335.05M
Tax Assets00000
Other Non-current Assets7.19M9.69M8M7.71M17.34M
Total Non-current Assets305.65M219.59M196.27M293.73M507.56M
Total Assets841.32M1.01B824.32M1.4B1.42B
Account Payables21.09M25.61M21.51M20.37M22.34M
Short-term Debt0958K10.08M11.52M41.18M
Tax Payables00000
Deferred Revenue00052.37M1.61M
Other Current Liabilities16.47M22.89M39.81M21.11M80.08M
Total Current Liabilities71.86M84.62M102.68M179.67M202.45M
Long-term Debt142.84M609.62M607.37M645.6M1.12B
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)87M0000
Other Non-current Liabilities183.53M301.55M380.16M599.19M657.76M
Total Non-current Liabilities525.6M1.04B1.11B1.36B1.88B
Total Liabilities597.46M1.12B1.21B1.54B2.08B
Common Stock84K94K102K118K123K
Retained Earnings(1.21B)(1.59B)(2.11B)(2.7B)(3.49B)
Accumulated OCI(869K)(3.59M)(10K)2.4M630K
Other Stockholders Equity00000
Minority Interest00000
Total Equity243.86M(107.9M)(386.32M)(135.37M)(659.63M)
Total Debt269.93M750.3M755.77M788.68M1.28B
Net Debt157.26M684.72M642.75M693.82M1.16B

Cytokinetics, Incorporated

NASDAQ:CYTK

Intrinsic Alpha fair value

Locked

Current Price

$51.32

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.